CohBar Inc. fell out of compliance with the Nasdaq Capital Market's audit committee requirements for continued listing.
The company lost compliance when Philippe Calais resigned from its audit committee Dec. 6.
CohBar has until its next annual stockholder meeting, on Dec. 9, 2019, to replace Calais and regain compliance. If the company's next annual stockholder meeting is held before June 5, 2019, the deadline will be on that date.
The noncompliance notice has no immediate effect on the listing of CohBar's common stock.
Menlo Park, Calif.-based CohBar develops mitochondria-based therapeutics for diseases associated with aging and metabolic dysfunction.